President Donald Trump has locked in a sweeping set of pricing agreements with nine of the world's biggest drugmakers, promising to pull some of the most expensive medicines on the U.S. market closer ...

The GLP-1 fight just entered a new round, and it highlights why these three out-of-favor drug makers are worth a deep dive.